Cannabinoids have demonstrated potential as treatments for liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and fibrosis.
In a unique and potentially transformative drug delivery technique, PreveCeutical Medical is engineering the world's first nose-to-brain drug delivery platform.
MA Analytics is finalizing the policies and procedures as well as their operations ahead of the laboratory's final inspection by the State of Nevada
A new study suggests that smoking cannabis may lower the number of prescription opioids needed to produce pain relief.
The Cannabis Science, Dana-Farber research team has now begun next level planning to bring this efficacious research to full commercialization.
Originally developed for the U.S. military to test for nerve agents and toxic metals, GreenLite technology has been repurposed to detect pesticides and toxic metals in cannabis.
WeedMD will contribute samples of 25 strains for cannabinoid composition analysis to create comprehensive profiles of each strains unique characteristics.
The report found that although positive steps have been taken to better regulate recreational cannabis in the state, further work is required.
As cannabis has anti-inflammatory properties there may be potential for topical cannabis to improve conditions such as acne, psoriasis and eczema by reducing the inflammation associated with these diseases.